D.E. Shaw & Co
ATXS

D.E. Shaw & Co’s Astria Therapeutics ATXS Stock Holding History

D.E. Shaw & Co’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-82,925
Closed -$604K – 4588
2025
Q3 		$604K Buy
82,925
+529
+0.6% +$3.58K ﹤0.01% 3762
2025
Q2 		$442K Buy
82,396
+63,639
+339% +$308K ﹤0.01% 3697
2025
Q1 		$100K Buy
18,757
+7,382
+65% +$51.6K ﹤0.01% 4018
2024
Q4 		$102K Buy
11,375
+1,207
+12% +$12.8K ﹤0.01% 4166
2024
Q3 		$112K Sell
10,168
-14
-0.1% -$156 ﹤0.01% 4241
2024
Q2 		$92.7K Buy
+10,182
New +$99.4K ﹤0.01% 4174
2022
Q2 		– Sell
-24,809
Closed -$166K – 5334
2022
Q1 		$166K Sell
24,809
-13,398
-35% -$79.8K ﹤0.01% 4912
2021
Q4 		$206K Sell
38,207
-7,863
-17% -$51.7K ﹤0.01% 4868
2021
Q3 		$407K Buy
+46,070
New +$441K ﹤0.01% 4201
2016
Q3 		– Sell
-232
Closed -$52K – 3362
2016
Q2 		$52K Hold
232
– – ﹤0.01% 3285
2016
Q1 		$70K Sell
232
-205
-47% -$70.7K ﹤0.01% 3309
2015
Q4 		$208K Sell
437
-91
-17% -$43.7K ﹤0.01% 3542
2015
Q3 		$256K Buy
+528
New +$377K ﹤0.01% 3408

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's ATXS Position: Q4 2025 in Review

D.E. Shaw & Co sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 82,925 shares — an estimated $604K sold.

D.E. Shaw & Co first reported a position in ATXS in Q3 2015 and held it in 13 quarters. The position peaked at $604K in Q3 2025. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

  • D.E. Shaw & Co reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 82,925 Astria Therapeutics shares in Q4 2025, an estimated $604K.
  • D.E. Shaw & Co first reported a position in Astria Therapeutics in Q3 2015 and held it in 13 quarters.
  • D.E. Shaw & Co's Astria Therapeutics position peaked at $604K in Q3 2025.
  • 141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on D.E. Shaw & Co's 13F filing for Q4 2025, filed 17 Feb 2026.